Bioengineering Extracellular Vesicles for the Treatment of Cardiovascular Diseases

Adv Biol (Weinh). 2022 Oct;6(10):e2200087. doi: 10.1002/adbi.202200087. Epub 2022 Jul 1.

Abstract

Cardiovascular diseases (CVD) remain one of the leading causes of mortality worldwide. Despite recent advances in diagnosis and interventions, there is still a crucial need for new multifaceted therapeutics that can address the complicated pathophysiological mechanisms driving CVD. Extracellular vesicles (EVs) are nanovesicles that are secreted by all types of cells to transport molecular cargo and regulate intracellular communication. EVs represent a growing field of nanotheranostics that can be leveraged as diagnostic biomarkers for the early detection of CVD and as targeted drug delivery vesicles to promote cardiovascular repair and recovery. Though a promising tool for CVD therapy, the clinical application of EVs is limited by the inherent challenges in EV isolation, standardization, and delivery. Hence, this review will present the therapeutic potential of EVs and introduce bioengineering strategies that augment their natural functions in CVD.

Keywords: cardiovascular disease; cargo loading; extracellular vesicles; nanotherapeutics; targeted delivery.

Publication types

  • Review
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bioengineering
  • Biomarkers
  • Cardiovascular Diseases* / diagnosis
  • Drug Delivery Systems
  • Extracellular Vesicles*
  • Humans

Substances

  • Biomarkers